Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 2/20 | 0.50 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | KDM5A | P29375 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 2/20 | 0.38 |
| ▸ | MLNR | O43193 | 1/20 | 0.38 |
| ▸ | TGM2 | P21980 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16000488 | 0.88 | SYK (0.49) | SYKNOS3NOS1NOS2EPHX2 | |
| SCHEMBL16002960 | 0.84 | CCR3 (0.51) | SYKNOS3NOS1NOS2EPHX2 | |
| SCHEMBL16002957 | 0.83 | CHRM2 (0.52) | SYKEPHX2HCRTR2CHRM2 | |
| SCHEMBL16002921 | 0.81 | CHRM2 (0.52) | SYKCHRM2TACR1 | |
| SCHEMBL16002936 | 0.77 | PLK1 (0.55) | SYK | |
| SCHEMBL16002983 | 0.76 | SYK (0.51) | SYKTACR1 | |
| SCHEMBL1806957 | 0.75 | ALDH1A1 (0.47) | EPHX2CHRM2 | |
| SCHEMBL16003044 | 0.74 | EPHX2 (0.68) | NOS2EPHX2EPHX1KDM5A | |
| SCHEMBL13866413 | 0.73 | EPHX1 (0.55) | EPHX2EPHX1 | |
| SCHEMBL13866415 | 0.73 | GAA (0.60) | EPHX2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9145391-B2 | Bipyridylaminopyridines as Syk inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-09-29 | — | — | US | disclosed |
| US-20140249130-A1 | BIPYRIDYLAMINOPYRIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2014-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249130-A1 | BIPYRIDYLAMINOPYRIDINES AS SYK INHIBITORS | SYK, BTK, LCK | SYK 1/4885NOS3 513/4885NOS1 187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.